Akari Therapeutics
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.akaritx.com
Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- AKARI Therapeutics
- Registration Number
- NCT05061771
- Locations
- 🇺🇸
Tulane University Health Sciences Center, Los Angeles, California, United States
🇺🇸North Shore University Health System, Skokie, Illinois, United States
🇺🇸Dawes Fretzin Clinical Research Group LLC, Indianapolis, Indiana, United States
Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- AKARI Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT04784455
- Locations
- 🇬🇧
St. Georges University Hospital, London, United Kingdom
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Duke University Medical Center, Children's Health Center, Durham, North Carolina, United States
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
- Conditions
- Atopic Keratoconjunctivitis (AKC)
- Interventions
- Drug: rVA576Other: Placebo
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- AKARI Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT04037891
- Locations
- 🇬🇧
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
- Conditions
- Bullous Pemphigoid (BP)
- Interventions
- Drug: rVA576
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- AKARI Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT04035733
- Locations
- 🇳🇱
UMCG Groningen, Groningen, Hanzeplein 1, Netherlands
🇩🇪University of Lubeck, Lubeck, Germany
rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: rVA576 (Coversin)
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- AKARI Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT03829449
- Locations
- 🇵🇱
Instytut Hematologii i Transfuzjologii, Warsaw, Poland
Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Drug: rVA576Other: Standard of care (SOC)
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- AKARI Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT03588026
- Locations
- 🇱🇰
University of Kelaniya, Faculty of Medicine, Thalagolla Road, Colombo, Sri Lanka
🇰🇿Almaty City Hospital No.7, Almaty, Microdistrict Kalkaman, Kazakhstan
🇱🇹Vilnius University Hospital Santaros Klinikos , Santariškių St. 2, LT-08661,, Vilnius, Lithuania
Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AKARI Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT03427060
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- AKARI Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT02591862
- Locations
- 🇳🇱
Dr Saskia Langemeijer, Nijmegen, Netherlands